Therakos CELLEX Photopheresis Kit
FDA premarket approval P860003/S103 · decided 2023-06-16
Approval details
- PMA number
- P860003
- Supplement
- S103
- Supplement type
- Normal 180 Day Track
- Supplement reason
- Change Design/Components/Specifications/Material
- Trade name
- Therakos CELLEX Photopheresis Kit
- Generic name
- System, photopheresis, extracorporeal
- Applicant
- Therakos Development Limited
- Date received
- 2020-09-25
- Decision date
- 2023-06-16
- Days to decision
- 994 days
- Decision code
- APPR
- Product code
- LNR
- Advisory committee
- Gastroenterology, Urology
- Expedited review
- No
- Location
- Dublin
- Statement
- Approval for resin changes for the CELLEX® Photopheresis Procedural Kit.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.